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Abstract
The perception that many promising results from basic biomedicine have not systematically con-
tributed to medical treatments and, ultimately, health care improvements, has led to a wide range
of publicly funded initiatives aiming at facilitating the ‘translation’ of scientific discoveries into
beneficial applications and practices. Many of these initiatives have been branded as
‘Translational Research’ (TR), a term widely applied to large research programmes, research
activities, and even academic journals. With the popularity of the term, a debate has emerged
about the models of research that are to be considered ‘translational’. Consequently, the ways in
which TR should be analysed and, more specifically, the approaches to the evaluation of TR pro-
grammes are also the subject of debate. Given the substantial investments in TR programmes,
the definition of TR evaluation strategies and approaches has become an important element of
the policy process. In a context of ambiguity about the type of activities to be considered as TR,
evaluation approaches and practices can play an important role in determining what actions and
outcomes are conceived, in practice, to be relevant and significant, and in doing so, shaping the
future nature of TR initiatives. This article discusses the dominant approaches to TR evaluation
and proposes an alternative evaluation framework, which would have implications both for TR
evaluation processes and for the future shaping of TR programmes.
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Introduction
The pathways between basic science, clinical practice, and health
outcomes are multifaceted and complex. Analysis of these path-
ways has attracted the interest of the biomedical research commu-
nity and public health agencies. Researchers and funding agencies
are concerned with the ways in which scientific breakthroughs and
evidence-based clinical findings are converted into practices with
beneficial health impacts, including, but not limited to, therapies
and medical guidelines. This interest is driven largely by the per-
ception that many promising results from basic biomedicine have
not contributed systematically to medical treatments and, ultim-
ately, health care improvements.1 In response, a wide range of
publicly funded initiatives has been set up to address this problem.
As the main aim of these initiatives is to facilitate the ‘translation’
of scientific discoveries into beneficial applications and practices,
many of these initiatives have been branded ‘Translational
Research’ (TR).
TR has become a very popular term and has been applied to large
research programmes, research activities, and even academic jour-
nals, and has attracted the interest of biomedical scholars and institu-
tions (Marincola 2003; Zerhouni 2007; Woolf 2008). The origins of
the concept can be traced back to the 1990s, when the US National
Cancer Institute developed the Specialized Programs of Research
Excellence (SPORE) (Lander and Atkinson-Grosjean 2011). Starting
in 1992, SPORE provided support for efforts to facilitate the ‘trans-
lation’ of basic discoveries generated at academic centres, into new
interventions aimed at preventing and treating various types of can-
cer. Since then, several policy initiatives have focused on the trans-
formation of basic knowledge into health benefits. In the USA, the
National Institutes of Health (NIH) launched the Roadmap Initiative
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(Zerhouni 2003), the Clinical and Translational Science Awards
(Heller and de Melo-Martı´n 2009), and, in December 2011, a $575
million National Center for Advancing Translational Sciences.2 TR
initiatives have also been launched in the European Union (EU) and
its Member States. Some are explicitly labelled TR programmes,
others have similar objectives and rationales, although they are
labelled differently. For example, in 2006, the Spanish Ministry of
Health launched the Networked Centres of Biomedical Research
(CIBER),3 together with other research initiatives to facilitate the re-
lationship between basic scientists and healthcare practitioners (Rey-
Rocha and Martı´n-Sempere 2012).
Often the more popular the policy concept, the more ambiguous
it becomes. This clearly applies to TR, and there is emerging debate
on the models of research which are considered to be ‘translational’
and the nature and characteristics of a putative TR discipline
(Littman et al. 2004). Consequently, the ways in which TR should
be analysed, and, more specifically, the approaches to the evaluation
of TR programmes are similarly open to debate. Given the substan-
tial investment in TR programmes, the definition of TR evaluation
strategies has become important for policy definition and implemen-
tation. Given the ambiguity about the type of activities that can be
considered TR, evaluation approaches and practices can play an im-
portant role in determining these activities, thus shaping the nature
of TR initiatives. This article discusses the dominant approaches to
TR evaluation and proposes an alternative evaluation framework,
which may have implications for the way in which TR programmes
may be defined in the future.
First, we provide an overview of the different ways in which TR
is conceptualized. Many approaches consider TR as activities that
bridge gaps in a continuum stretching from basic research to health
outcomes (Morris et al. 2011). Other views emphasize the research
process, how different groups interact, and how their roles may be
redefined by a TR initiative (Currie and White 2012).
Second, we discuss different evaluation approaches associated
with these different views of TR. One of the dominant approaches
focuses on the outputs generated at different points of the ‘transla-
tional research continuum’ and estimates the time it takes to pro-
duce them. A focus on ‘what’ and ‘when’ implies a TR evaluation
approach that attempts to identify results and how they differ from
what would have been achieved in the absence of the initiatives
being assessed. It should be emphasized that this focus on outputs
may derive from an explicit view of TR as addressing ‘translational
gaps’ along a ‘TR continuum’, or may emerge without any explicit
‘theory’ of the processes and objectives of TR. TR then is measured
against success criteria based on the generation of outputs that are
no different from the outputs generated by traditional research.
Note that, in the absence of a ‘programme theory’, the objectives of
TR will, de facto, be defined by the evaluation strategy chosen.
Our proposal is to focus, instead, on ‘how’ research is carried
out, on the processes of collaboration and exchange that can be
attributed to TR initiatives. To this end, we develop an alternative
TR evaluation framework that focuses on understanding the proc-
esses of change across the divides that hinder the application of the
capabilities and knowledge generated by basic biomedicine to health
care. The extant literature attributes the low level of practical appli-
cation of biomedical research to a variety of causes, including:
(1) the divide between the interests and skills of the different profes-
sional communities and disciplines, such as basic scientists, clinical
scientists, and clinical practitioners (Currie and White 2012); (2) the
problem of communication among fields that are becoming more
complex and specialized (Littman et al. 2004); and (3) the existence
of institutional barriers and occupational boundaries that hinder the
effective flow of knowledge and interests (Lander and Atkinson-
Grosjean 2011).
Third, following the conceptual framework proposed by Ron
Boschma (2005), we suggest that TR initiatives can operate by gen-
erating ‘proximities’ along five different analytical dimensions: cog-
nitive, social, organizational, institutional, and geographical. We
define these dimensions and argue that a TR support activity can be
defined by the type of proximity it targets. We illustrate this by
referring to two Spanish biomedical research programmes, and con-
clude by exploring the implications of using this alternative way of
framing TR evaluation.
TR: a variety of approaches
The development of TR initiatives reflects the perceived need to in-
crease the chances that scientific discoveries will lead to benefits for
patients, and to improve the alignment between biomedical research
in biomedicine and health needs. TR emerged at a time when other
initiatives aimed at facilitating the ‘valorization’ or uptake of research
by socio-economic actors were flourishing (Bozeman and Boardman
2004). TR has become part of the policy discourse, justifying many
current research-funding programmes. The inclusion of the TR dis-
course in the policy agenda has been accompanied by intense aca-
demic discussion among biomedical scholars. What policy or
management measures are needed to speed up the process of applica-
tion of biomedical research advances to clinical practice? How should
we characterize TR and evaluate TR initiatives? The development of a
conceptual framework to describe the TR process and evaluate TR
initiatives has become a theme in the academic research literature (for
a review of the discussion see Drolet and Lorenzi, 2011).
The linear model of TR
The most popular representations of TR assume a linear model of
innovation (Rogers 2003), prioritizing basic research as the primary
source of new discoveries, which subsequently are developed into
therapeutic solutions and finally are diffused to patients and the
wider society. In the medical field, the adoption of this approach
sees basic scientists at the origin of the innovation process, produc-
ing a large amount of fundamental knowledge at the molecular or
cell level, some of which will be relevant for the development of new
drugs or therapies. The fundamental knowledge generated by basic
scientists moves forward through the stages of a ‘translational con-
tinuum’, until eventually, it is translated into specific benefits for pa-
tients or the general population, in the form of new drugs, devices,
and new prevention and treatment options. Every step in this linear
progression addresses a specific problem and is undertaken by a spe-
cialized group of researchers. In this view, the successful application
of new knowledge is dependent on the successful completion of
every one of the stages along the ‘translational continuum’ (Van der
Laan and Boenink 2012) (Fig. 1).
Indeed, the idea of moving forwards through stages, which has
been described as going from ‘bench to bedside’, is thoroughly in-
grained in most of the existing conceptualizations of TR—in aca-
demia and among practitioners and policymakers (Sung et al. 2003;
Khoury et al. 2007). This stage approach to TR does not differ sub-
stantially from the classic linear stage process, which characterizes all
clinical research. What makes TR approaches different is the explicit
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identification of which steps in these processes are more problematic
and slow the progression towards application and health benefits.
Thus, TR models identify a series of translational chasms, gaps, or
blocks that need to be bridged (Woolf 2008). These chasms are
viewed as obstacles and typically are described using what has come
to be known as a ‘T-terminology’ (Dougherty and Heller 1994),
which consists of a structured list of (T)ranslation gaps to be bridged.
According to these models, the main objective of TR is to bridge
these gaps so as to facilitate more rapid movement of knowledge
through the successive steps from basic research to application.
One of the first models adopting a T-terminology was developed
by the US Institute of Medicine’s Clinical Research Roundtable,
which identified two main gaps: T1 and T2. The first chasm (T1) is
related to the transfer of basic discoveries into human clinical test-
ing; the second, T2, refers to the dissemination and adoption of suc-
cessful clinical discoveries into daily clinical practice. As TR
research has developed, more detailed models have been proposed,
which include more T-phases and more chasms to be bridged.
Westfall et al. (2007) proposed a TR model beginning at T1, where
knowledge coming from basic science moves to human clinical re-
search through the development of Phase I and Phase II clinical tri-
als. According to this model of TR, the process starts at the ‘bench’,
with fundamental discoveries in molecular biology, genetics, and
other basic sciences which may be of interest for understanding
human health. The T2 chasm comprises the activities related to the
translation of initial human testing results into clinical practice.
Activities such as Phase III and Phase IV clinical trials, and observa-
tional studies and survey research, are considered to occur at this
stage. The final gap (T3) deals with the translation into practice,
and the dissemination of the new clinical treatment (e.g. through the
development of guidelines for clinical practice, patients and the gen-
eral population). Other models break down the translational con-
tinuum even further by proposing an additional final gap (T4),
which emerges in the effort to advance towards real-world health
outcomes by promoting the adoption of evidence-based recommen-
dations by health practitioners (Khoury et al. 2007).
Some of the proponents of these linear TR models acknowledge
that knowledge can flow also from ‘bedside to bench’. For instance,
Marincola (2011) stresses that hypotheses tested in basic research
experiments can be based on observational evidence from practi-
tioners. Research based on clinical evidence is particularly important
because it provides factual knowledge collected through practitioner
observation (e.g. through direct contact with patients), which can be
translated into specific hypotheses to be tested in the lab, or lead to
ideas that open up new research avenues. However, although the bi-
directional nature of TR is acknowledged in most TR models, the
majority of TR policy initiatives pursue or are based implicitly on a
unidirectional ‘bench to bedside’ understanding of knowledge gener-
ation and application, as reflected in the terminology referring to
consecutive gaps (T1, T2, T3, . . . ) which need to be bridged.
This focus on the identification of T-gaps has posed a series of
challenges that have framed much research on TR analysis and
evaluation and some problems. In analysing TR to find solutions to
different translational gaps, the identification of these gaps and the
different views of stakeholders about how to address them, can lead
to different understandings of what TR is about (Van der Laan and
Boenink 2012) and what specific skills scientists should develop to
support TR (Rubio et al. 2010). Littman et al. (2007) point out that,
for academics, TR represents (1) a channel to test whether novel
ideas generated by basic science have the potential to translate into
practical applications, (2) an opportunity to gain observational in-
sights and develop novel scientific hypotheses to be tested in the lab,
and (3) a means to gain legitimacy and improved access to research
funding. However, for clinical practitioners such as physicians or
clinical staff, TR is viewed primarily as responding to the need to
shorten the path between scientific evidence and actual practice
(Davis et al. 2003). Business organizations view TR as a process to
accelerate the development of a new drug or therapy and as an op-
portunity to make go/no-go decisions at an early stage in the bio-
medical innovation process—potentially resulting in major savings
by avoiding unproductive investments. Also, the fact that public or-
ganizations conduct TR is seen by industry as an opportunity to
save on research whose returns are very uncertain (Littman et al.
2007).
The interactive-process model of TR
Although different stakeholders may hold different views on the ob-
jectives of TR, there is a consensus on specific ‘gaps’ among the suc-
cession of translational gaps. This ‘gap-centred’ perspective,
implicitly or explicitly sees knowledge accumulating through differ-
ent stages from fundamental to applied research. However, some
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Figure 1. A model of Translational Research Continuum.
Research Evaluation, 2015, Vol. 0, No. 0 3
scholars have expressed concern about the adequacy of a linear TR
model to frame analysis and develop policy strategies (Graham et al.
2006; Littman et al. 2007; Marincola 2011). A linear TR model
builds implicitly on the theoretical separation between basic and
applied research. Although this separation is widely used when talk-
ing about science and technology policy, numerous studies show
that it is problematic. In particular, fundamental knowledge can be
sought in order to solve an applied problem, a` la Pasteur. This argu-
ably is a different form of research, ‘use-inspired basic research’
(Stokes 1997), which fits well with the TR goal of generating know-
ledge with an explicit focus on patient applications and public
health benefits. However, a TR model based on a linear progression
from basic science to health applications cannot account for the ex-
istence of ‘user-inspired basic research’. Also, a linear conceptualiza-
tion of TR may clash with the evidence on how medical innovation
processes emerge and develop in the health sector. The medical re-
search process does not always proceed linearly. Rather, innovation
scholars conceptualize it as an iterative process in which insights
provided by one group of stakeholders spurs advancement in sur-
rounding professional and epistemic groups (Consoli and Mina
2009; Hobin et al. 2012).
The idea that knowledge moves forwards and backwards along
the unidimensional line of the TR continuum may partially capture
the view of a dynamic relation between basic and applied research
and the application of its results, but cannot account for the exist-
ence of a different type of research, involving scientists who carry
out fundamental research while are also systematically considering
potential health applications. In fact, the participants in TR can
interact, playing different roles simultaneously. It has been argued
that the progress of biomedical research depends increasingly on
close collaboration between researchers, practitioners, medical insti-
tutions, patient communities, and research sponsors (Meslin et al.
2013). Here, the role of ‘boundary spanners’, that is, actors who fa-
cilitate communication across different communities, is particularly
important (Swann et al. 2007; Lander and Atkinson-Grosjean
2011). Boundary spanners are individuals who engage in significant
transactions with members of other communities, facilitate know-
ledge exchange between groups, and manage intergroup conflicts
(Richter et al. 2006).
From this perspective, clinical scientists working at the interface
between basic scientists and health practitioners could play a crucial
‘boundary spanning’ role, intermediating between the needs and ob-
jectives of the different actors, and conveying knowledge in a fast
and timely manner (Kelley et al. 2012). To be effective, clinical sci-
entists need management and coordination skills and knowledge of
the different ‘languages’ used by the diverse ‘epistemic cultures’ of
basic scientists and clinicians (Roberts et al. 2012). This is more eas-
ily achieved if individual researchers engage in both basic and clin-
ical work. It has been suggested that clinicians working at the
interface between basic scientists and the final beneficiaries of the re-
search (e.g. patients) can contribute to the establishment of new
partnering mechanisms with patients, with the objective of assessing
therapies and performing observational studies (Kelley et al. 2012).
However, the links among the diverse groups of actors involved in
the development of new drugs and therapies can be problematic.
From this perspective, the main objective of TR can be redefined.
Rather than focusing on bridging the gaps between successive stages
in the TR process, the emphasis is placed on the roles and inter-
actions of different actors who traditionally have fulfilled very speci-
alized and compartmentalized roles. For instance, basic scientists
may become involved in TR when conducting ‘user-inspired re-
search’ in close contact with, among others, clinicians and patients.
Another form of TR can emerge when patient organizations collab-
orate with researchers to identify research problems. Clinicians can
act as ‘boundary spanners’ helping others make connections. There
are many different ways to establish much closer working inter-
actions among the different actors in the research process. Instead of
seeing TR as addressing the problems that appear at specific points
in a traditional, staged, linear research system, in our approach, TR
addresses the separation between different groups of researchers and
stakeholders throughout the process, linking research to the devel-
opment and application of solutions to health problems. To do so,
TR focuses on processes—on how the sharing, exchange, and acqui-
sition of knowledge are articulated and how different actors get
involved in this process.
TR evaluation: gaps and lags versus proximities
Different ways of understanding the notion of TR open the way to a
variety of translational policies and initiatives with different object-
ives and logics. These various notions are associated also with differ-
ent ways of evaluating TR initiatives. In the preceding section, we
defined two main, contrasting, views of TR. They lead to different
approaches to the evaluation of TR.
Gaps and lags: evaluating the translational continuum
If TR is seen as the attempt to bridge a series of sequential gaps that
hamper the translation of research results into socially beneficial ap-
plications, its evaluation should focus on the specific gaps that TR is
supposed to address rather than the whole R&D process. The suc-
cess of a TR programme can then be defined by the extent to which
it has reduced or bridged these gaps. The diversity of evaluation
techniques that have been proposed reflects the different definitions
of these gaps and the different indicators used to measure how well
they have been bridged. Morris et al. reviewed 23 TR evaluation
papers and concluded that ‘different studies use different measures,
of different things, at different time points’. The authors argue fur-
ther that ‘understanding lags first requires agreeing models, defin-
itions and measures, which can be applied in practice’ (Morris et al.
2011).
This perspective assumes that the key indicator to assess TR ini-
tiatives is the time it takes for the different translational gaps to be
bridged and, therefore, for the research to be translated into treat-
ments and other health-improving measures. Time lags are used also
by Trochim et al. (2011). They develop a generic approach to TR
evaluation and propose a flexible solution focusing on what they
consider to be the final objective of TR: the reduction in the time
needed to develop new clinical practices and drugs patients. They
adopt a generic linear TR model to identify ‘markers’ in the transla-
tion process and to assess the time that it takes for outputs to move
across these markers. The identification of these markers is flexible
and does not require a choice between one and another model of
TR. There is flexibility also in the direction of the activity across
markers, allowing for both ‘bench to bedside’, and ‘bedside to
bench’ movements. The approach suggested by Trochim et al.
focuses on the outputs of TR, and on the time it takes for the output
of a specific activity to be translated into a different type of output
identified by another marker. In other words, this form of
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evaluation is concerned with TR outputs rather than how these out-
puts are achieved.
Several TR evaluations have adopted this procedure. Even when
the TR programmes themselves are unclear in the definition of their
goals, time lag studies have become an increasingly dominant ap-
proach to their evaluation. In these evaluations, the gap between the
different research phases and the outputs they generate ceases to be
an indicator of success and is converted into the objective of TR:
shortening the time between different research stages becomes what
TR is about. It could be argued that there is a risk of the tail of
evaluation wagging the dog of TR. In other words, how success is
measured may define the nature of the research objectives being pur-
sued. Further, TR evaluations that focus on measuring the time lags
between different research stages pay little attention to the standard-
ization of such lag measurements and to understanding the factors
underlying the measured lags (Morris et al. 2011). This presents
problems for evaluation practice; for instance, time lags may be
poorly assessed if the differences between scientific domains are not
considered in the estimation (Contopoulos-Ioannidis et al. 2003).
A focus on outputs and time lags has some advantages. For in-
stance, it allows the use of traditional indicators, such as scientific
publications, by linking them to a ‘marker’. This may be convenient
since traditional indicators are easily available, but their application
may reinforce some of the processes and practices that TR is sup-
posed to combat. For instance, basic scientists can be assessed ac-
cording to their published output, particularly the time it takes for
publication to take place; however, this takes no account of how the
outputs were generated, how the different research steps were
defined, and the roles of the different actors involved in the process.
An understanding of TR that takes account of how the research and
innovation processes are organized calls for a different evaluation
approach. In the next section, we formulate an evaluation frame-
work, which we argue is better suited to addressing the ways in
which TR initiatives affect the research and application processes.
Proximities: evaluating interaction processes
Our proposal is to focus on how TR programmes affect the ways in
which research objectives are defined, research is conducted, and its
results applied in practice. We posit that TR initiatives attempt to
address problems in the organization and management of biomed-
ical research by bridging the divide between different actors involved
in the development of new drugs, therapies, diagnostics, or public
health practices. These actors include the doctors and patients
involved in the identification and definition of therapeutic and
health problems, the researchers defining and addressing the rele-
vant fundamental research challenges, and the clinicians and doctors
developing and testing solutions. These different groups belong to
different organizations, follow different implicit and explicit rules,
and respond to different sets of incentives and performance criteria.
These conflicting logics (Sauermann and Stephan 2013) and differ-
ent epistemic cultures (Knorr-Cetina 1999) can make it difficult to
align objectives and establish information flows. Stakeholders sepa-
rated by institutional and organizational boundaries find it difficult
to communicate needs and results. For instance, Ferlie et al. (2005)
show that maintaining institutional separation among different med-
ical professions is a major barrier to the development of medical
innovations.
Thus, TR initiatives can seek to reduce some of the divides
among biomedical researchers, clinical doctors, general
practitioners, regulators, etc. It is important to emphasize the net-
worked and non-linear nature of these social interactions; for in-
stance, basic research can be influenced by insights from general
practitioners and regulators, without the mediation of clinical doc-
tors. We would suggest that these interactions may be difficult to
operationalize due to the various types of distance between these dif-
ferent groups. Following Boschma (2005), learning processes and
knowledge exchange interactions are facilitated and strengthened by
five forms of proximity: cognitive, social, organizational, institu-
tional, and spatial.
Cognitive proximity reflects similarities in the way people per-
ceive, interpret, understand, and evaluate the world (Wuyts et al.
2005). A certain degree of cognitive proximity, that is, the extent to
which the actors share a similar knowledge base, is a prerequisite
for interactive learning, as it facilitates effective communication and
a common reference space to process and transfer complex informa-
tion and knowledge. However, as Nooteboom (2000) and Boschma
(2005) point out, both too much or too little cognitive proximity
can be detrimental to innovation and learning processes. A high level
of cognitive proximity can result in the exchange of redundant
knowledge due to the similarity in the knowledge sources. Too little
cognitive proximity can lead to the exchange of information that is
not fully understood by the actors, rendering the communication in-
effective. Thus, research on cognitive proximity claims that there is
an optimal level of cognitive proximity for interactions between
actors to be productive (Boschma and Frenken 2011).
Social proximity refers to relations built on common experience,
friendship, and kinship, which can facilitate interaction and commu-
nication based on mutual trust and reciprocity. As social proximity
between the actors increases, they know one another better commu-
nication becomes easier.
Organizational proximity refers to the governance structure
shaping the interactions between actors. High organizational prox-
imity is often associated with a hierarchical structure governing the
actors’ interactions, while low organizational proximity is generally
associated with a flat governance structure or arms’ length inter-
actions among the actors.
Institutional proximity refers to the norms, rules, and values that
influence how actors behave. Large institutional distance, promoting
behaviour that responds to different, potentially conflicting, sets of
incentives or values, may impose serious impediments to fruitful
learning interactions among the actors. For example, the institu-
tional distance between universities and firms is considerable be-
cause their incentives and norms differ significantly. Institutional
proximity contributes to reducing uncertainty among the actors,
even in the absence of previous social interaction (Lagendijk and
Lorentzen 2007). In the biomedical field, the institutional distance
between different occupational and professional boundaries repre-
sents a major barrier to the exchange of knowledge and the spread
of innovations (Ferlie et al. 2005; Currie and White 2012).
Finally, geographical proximity refers to the spatial or physical
distance between actors. This matters in knowledge dynamics be-
cause spatial co-location favours the exchange of knowledge that is
complex or difficult to transfer (i.e. tacit knowledge) (Ponds et al.
2007; Frenken et al. 2012; D’Este et al. 2013).
All these types of proximity are interrelated. Some may be com-
plementary, others may act as substitutes. For instance, Harrison
(1992) and Howells (2002) argue that geographical proximity facili-
tates face-to-face interactions, favouring trust-based relationships
and knowledge exchange, suggesting a reinforcing effect of spatial
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proximity on social proximity. In contrast, some proximity dimen-
sions may be substitutes for each other: barriers to knowledge ex-
change posed by geographic distance might be overcome if the
interacting partners share a well-defined division of labour (i.e. or-
ganizational proximity) (Rallet and Torre 1999).
The main challenge for TR programmes is developing interven-
tions that generate a configuration of distances between actors that
is appropriate for the specific goals of the programmes. Distance
problems can be addressed along one or more of the dimensions re-
viewed above. For instance, initiatives can be designed to improve
communication and understanding between patients, clinicians, and
researchers (addressing cognitive distance), to introduce coordin-
ation mechanisms across different organizations involved in the
research and application processes (addressing organizational dis-
tance), to align their incentives and norms (addressing institutional
distance), or to improve trust and cohesion among actors (address-
ing social distance). In other words, different TR initiatives may be
aimed at reducing the different distances among the actors involved
in biomedical research and the application of its results.
TR evaluation: increasing proximities and
‘programme theories’
The first step of an alternative TR evaluation strategy is to deter-
mine the, implicit or explicit, ‘programme theory’ underpinning the
TR initiative under study. In other words, we need to define the pol-
icy goals in terms of the proximities that are to be improved and the
process by which such improvements are expected to occur. As
argued above, while the ‘gaps and lags’ approach to evaluation
focuses on outputs and the time it takes to progress from one output
to another, in a proximities approach, the attention is on the re-
search and knowledge utilization processes. This is in line with cur-
rent proposals to focus research impact evaluations on the processes
by which impacts are generated (Kok and Schuit 2012).
How TR programmes pursue their goals will vary across initia-
tives. For example, a TR project may be aimed at facilitating TR by
merging two laboratories. In this case, the TR programme logic is
focused on geographical and organizational proximity. In other
cases, laboratories (e.g. in a university and a hospital) are expected
to interact, but to remain separate, with joint activities organized to
foster knowledge exchange. In this case, the logic focuses on over-
coming institutional distance through social and cognitive proxim-
ities. Drawing on two contrasting Spanish examples, the August Pi i
Sunyer Biomedical Research Institute (IDIBAPS) centre and the
CIBER networks initiative, we show how the dimensions of proxim-
ity can be used to describe the different ‘programme theories’ of TR
initiatives.
Collaborative centres seeking to enhance interaction via
spatial proximity: the case of IDIBAPS
IDIBAPS is a TR centre which is located opposite to the Clinic
Hospital of Barcelona. It houses some 460 researchers with diverse
institutional affiliations: the Clinic Hospital, the University of
Barcelona, Spanish and Catalan research establishments Spanish
National Research Council (CSIC) and Catalan Institution for
Research and Advanced Studies (ICREA), and its own staff. It pro-
vides a space for researchers with different affiliations and expertise
to work together on different themes (e.g. biomarkers for oncology),
using common facilities (e.g. bioinformatics, biobanks, imaging
instrumentation). IDIBAPS can be described as a TR initiative pri-
marily acting mainly upon spatial proximity through the co-location
of laboratories and shared access to research facilities. This spatial
proximity is expected to generate other forms of proximity; for in-
stance, IDIBAPS work practices are expected to enhance trust and
collaboration among the actors (thus increasing social proximity).
Ultimately, these proximities should facilitate knowledge flows
(increasing cognitive proximity) among different cognitive areas.
Therefore, the evaluation of an organization like IDIBAPS should
seek to determine whether and how expectations about interactions
and cross-fertilization are being met.
Collaboration networks seeking to enhance interaction
via organizational proximity: the CIBERs
The CIBERs were established in 2006 by the Spanish Government
to promote excellence in biomedical research through the establish-
ment of stable cooperative research arrangements, which could be
defined as loosely coupled networks.4 The CIBERs were selected
based on an open call to biomedical research groups. Applicants had
to propose broad networks of research groups including universities,
public research organizations, hospitals, clinics, and research foun-
dations. Nine CIBER research networks5 were founded between
2006 and 2007, each focused on a specific pathology or disease, in
line with the strategic goals of the Instituto Carlos III (equivalent to
the US NIH), and with the explicit task of conducting TR.
Since members of the CIBERs continued to work in their own or-
ganizations, increasing spatial proximity was clearly not the object-
ive of the initiative. It was aimed at coordinating, through the
common legal and economic framework provided by the CIBER
platform, diverse biomedical groups within universities, hospitals,
and public research organizations. The CIBER platform provides an
articulated governance structure to catalyze coordinated actions
among the actors involved in the TR process. By connecting these
research groups through mechanisms and common practices and
decision-making processes agreed among all partners, the CIBER
platform aims to increase organizational proximity among a group
of heterogeneous research actors.
Although the groups belonging to a CIBER are only ‘loosely
coupled’, we can expect that, by setting some basic conditions for
the creation of common rules and shared expectations, the CIBERs
may provide the means to generate social proximity and through it
increase cognitive proximity. In other words, the CIBER networks
can be understood as an organizational arrangement, aimed primar-
ily at increasing the organizational proximity among the actors
(basic researchers, doctors, patient groups), who tend to be distant
in all dimensions. This greater organizational proximity should en-
hance social proximity, which should facilitate cognitive flows.
Analysing proximities and the implications for
evaluating TR
The need for a programme theory
TR addresses a problem that has organizational, social, and cogni-
tive roots: different communities with different practices and values
are involved in a process that is complex and difficult (Currie and
White 2012). The above two cases illustrate how two different ini-
tiatives, both labelled translational, have taken different approaches
and implicitly draw on different programme theories. The forms of
collaboration and interaction that we can expect from these
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initiatives are very different, and we suggest that when evaluating
them we should aim at understanding these differences. We are
interested in investigating how research objectives and projects are
designed, how the research is conducted, and how the application of
research results is and carried out. In other words, we need to under-
stand the variety of the processes involved in TR initiatives.
We argue that a process-based approach to evaluation has ad-
vantages over an evaluation focusing on outputs. First, focusing on
outputs provides no information on why an output has or has not
been generated according to the initial, implicit or explicit, expect-
ations of stakeholders. Second, existing practices could be relabelled
‘translational’ if TR policies and their evaluation were concerned
only with the generation of outputs and their identification. In the
case of TR, where there is ambiguity about what differentiates it
from other research forms, understanding how interventions operate
in practice and what processes they trigger is particularly important.
If TR initiatives are to be transformative, they must implement
changes in the way research and the development of clinical prac-
tices and therapies are conducted. This calls for an approach that
goes beyond ‘linear evaluation’ of TR. It requires an evaluation ap-
proach that focuses on these processes. Third, evaluation frame-
works are not neutral in relation to the objectives of an initiative.
The way in which a project is evaluated will affect how it is con-
ducted and how its performers conceive their objectives. Focusing
on specific outputs can implicitly suggest an intervention rationale
that is not concerned with the organization of the research or how
specific ‘translational gaps’ are addressed.
The proximities framework we have proposed help to focus at-
tention on the way the research is conducted and the specific aspects
that the initiative is intended to address. These aspects may some-
times be made explicit in the definition of the intervention, but they
may also only be implied in relation to how the initiative is imple-
mented. In this latter case, the framework could be used to explore
and develop a ‘programme theory’ for a TR initiative; in other
words, help policymakers to reflect on and explore the initiative’s
rationale. The cases described show how the framework can be used
to describe both the goals of a TR initiative and how these goals can
be achieved.
In adopting this approach, we are proposing that the immediate
goal of a TR initiative is to address the problem of the distances sep-
arating the different groups involved in medical research. The ‘trans-
lational gaps’ are due to excessive distance in one or more
significant dimensions. The groups involved in the translational pro-
cess have cognitive differences, are institutionally separate, and,
therefore, follow different rules, are faced with different types of in-
centives, and often are geographically dispersed. The definition of
an initiative and its evaluation must be flexible and allow for the
fact that too much proximity is not always desirable. For instance,
too large a cognitive distance can be problematic, but so can too
much cognitive overlap; cognitive proximity is positive only up to a
certain level. A specific programme theory must reflect this problem
of balance, and the interpretation of evaluation results must be sen-
sitive to this potential problem if there is a possibility that it may be-
come relevant.
The programme theory of a TR initiative should define expect-
ations about whether and how changes in proximity in one or more
dimensions caused by the intervention, will trigger shifts in the other
dimensions, and the effects of these changes on the development and
application of beneficial goods and services. These effects will be
mediated by changes to the way research is carried out. Increased
proximity can result in increased collaboration among the groups
involved in the various tasks that constitute the TR process (the def-
inition of fundamental and clinical research objectives, research, and
the application of its results). We can expect changes in proximity to
generate new interactions across groups, for instance, between re-
search performers and the diverse users and beneficiaries of the re-
search results, where knowledge moves back and forth along
various channels, and within networks, rather than along a linear
bedside to bench continuum.
We can identify other building blocks of a TR programme the-
ory. An intermediate outcome of increased proximities may be the
generation of complex interactions among the different groups
involved in the TR process. Although this may vary across initia-
tives, it is important to take into account the broad variety of poten-
tial stakeholders: basic researchers, clinical researchers,
technologists, practitioners (doctors, nurses, etc.) public health and
private industry managers, and patients. The ways in which stake-
holder groups interact can be traced and analysed using instruments
developed for the evaluation of the socio-economic impact of re-
search, such as those developed by the EU-funded Social Impact
Assessment Methods through the study of Productive Interactions
(SIAMPI) project (Molas-Gallart and Tang 2011; Spaapen and van
Drooge 2011), which focuses on the processes of collaboration that
can be linked to an initiative.
Moving forward: the operationalization of a
proximities approach to TR evaluation
This article has argued that a different approach to the evaluation of
TR is both possible and desirable and has shown that it will rely on
programme theories which will need to be developed for each differ-
ent TR initiative. The next step will be to operationalize the ap-
proach. While an output-based gaps and lags evaluation provides
easily measurable and potentially comparable results, a proximities
approach to evaluation will yield a description of the contextual
conditions in which the initiative was implemented and its effects on
the relevant processes. Narratives built on qualitative research tech-
niques could describe how the different proximities evolve through-
out an intervention. The narratives could be accompanied by
quantitative indicators; there are numerous examples from the in-
novation studies, economic geography, and management literatures
of attempts to measure different proximity dimensions. The main
approaches to developing proximity measures draw heavily on two
alternative sources: primary data mainly from surveys and fieldwork
research, and secondary data relying mainly on bibliographic and
patent information. Cognitive proximity has been measured as the
degree of overlap among the knowledge bases of potentially inter-
acting actors. This overlap can be captured at the individual level by
analysing the similarity between scientists’ publications or patents
profiles (Kotha et al. 2013). The cognitive distance between actors
can be captured by focusing on the patent subcategories in which
their discoveries are classified (Tzabbar 2009). Finally, science maps
offer a visualization of the overlap between actors across scientific
fields (Rafols et al. 2010) or patent categories (Kay et al. 2014).
Geographical proximity can be operationalized by measuring the
physical distance between the interacting partners, based on their
physical addresses (Laursen et al. 2011). Geographical information
based on postcodes allows the calculation of the ‘great circle’ dis-
tances between any two partners, while relative measures of dis-
tance, such as travel times between any two location points, have
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also been used (Ejermo and Karlsson 2006). Institutional proximity
refers to whether actors belong to similar or distinct types of institu-
tions (e.g. universities, hospitals, public research organizations,
etc.). Bibliometric analysis may be useful to explore actors affiliated
to more than one institution (e.g. a hospital and a university).
Organizational proximity is often measured by whether actors be-
long to the same organizational structure and, thus, answer to the
same authority. A more detailed approximation of organizational
proximity can be obtained by measuring the degree to which the or-
ganization is characterized by a flatter or more vertical chain of
command (Ponds et al. 2007), and the relative position of actors in
these ‘hierarchies’. Social proximity can be proxied by the extent to
which actors have interacted in the past, for instance, via co-
authorship or co-inventorship, and the duration of such linkages
(McFayden et al. 2009). Softer measures based on social network re-
search can be captured through surveys enquiring about the extent
to which actors have developed strong ties with each other, reflect-
ing a relationship of kinship, trust, and reciprocity (McFayden and
Cannella 2004).
Thus, there is a variety of techniques that can be adapted for
use in evaluation research. Use of a proximities framework does
not determine the research techniques to be employed; these need
to fit the specific circumstances of the individual initiative being
assessed. The activities supported by a TR initiative will be differ-
ent, be implemented in different contexts, and will have different
targets and objectives. For instance, the research techniques
applied to an initiative that focuses mainly on cognitive issues, will
be different from those applied to one that addresses institutional
differences.
Since the adequacy of a specific research technique will depend
on the specific TR evaluation problem and its context, it follows
that the outputs of TR evaluations will not and should not be dir-
ectly comparable. Calls for an approach based on a single set of re-
search techniques, yielding measurable and comparable indicators
of TR ‘output’, from our perspective, are out of place. An evaluation
approach that focuses on processes will seek to provide detailed in-
formation on the effects of an initiative starting at the level of those
groups directly involved in it. However, the way that this informa-
tion is shaped, and the indicators on which it is based will depend
on the type of initiative, its objectives, and the types of proximities
the programme is designed to address.
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Notes
1. Some analysts estimate that less than 10% of the most promising
biomedical discoveries resulted in any benefit to clinical practice
two decades later (Contopoulos-Ioannidis et al. 2003 Ioannidis
2004
2. www.ncats.nih.gov
3. CIBER is the Spanish acronym for ‘Centro de Investigacio´n
Biome´dica en Red’. http://www.isciii.es/ISCIII/es/contenidos/fd-
investigacion/fd-ejecucion/fd-centros-participados/fd-consor
cios2/cibers.shtml
4. Loosely coupled networks are organizational structures that
may help coordinate transactions among highly heterogeneous
partners, providing a balance between the mechanisms of con-
trol and flexibility. Loosely coupled networks lie somewhere be-
tween highly hierarchical organizational structures that impose
a strong degree of control and bureaucracy on learning-related
activities, and weakly articulated governance structures that
provide a fragile setting for building trust-based and sustainable
relationships.
5. Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN),
Epidemiology and Public Health (CIBER-ESP), Obesity and
Nutrition (CIBER-OBN), Hepatic and Digestive Diseases
(CIBER-EHD), Neurodegenerative Diseases (CIBER-NED),
Respiratory Diseases (CIBER-ES), Rare Diseases (CIBER-ER),
Mental Health (CIBER-SAM), and Diabetes and Metabolic
Associated Diseases (CIBER-DEM).
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